Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Myxofibrosarcoma: early-phase trial registry

2 of 6 indexed Myxofibrosarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Myxofibrosarcoma: 6 US clinical trials tracked, 2 recruiting.

Myxofibrosarcoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Tracon Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition myxofibrosarcoma

OPEN 2 | RECR 33% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Myxofibrosarcoma (this)33%
Open-enrollment share among volume-matched conditions near Myxofibrosarcoma

Myxofibrosarcoma lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Myxofibrosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Myxofibrosarcoma is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Myxofibrosarcoma research.

    Tracon Pharmaceuticals accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Myxofibrosarcoma enrolment sits around 139 participants.

    Median target enrolment is 139 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Myxofibrosarcoma research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Named interventions

Most-linked intervention names on Myxofibrosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CAB-AXL-ADC Biological
1 trials
PD-1 inhibitor Biological
1 trials
Envafolimab Biological
1 trials
Nanoplexed Poly I:C BO-112 Biological
1 trials
Proton beam radiation therapy Radiation
1 trials
Definitive Surgical Resection Procedure
1 trials
infusion of melphalan and dactinomycin Drug
1 trials
Isolated Limb Infusion Procedure
1 trials

US sites by state

Facility locations filed on Myxofibrosarcoma trials. A trial with sites in several states counts in each.

New York 3 trials
Missouri 3 trials
Massachusetts 3 trials
Illinois 3 trials
Colorado 3 trials
California 3 trials
Arizona 3 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Myxofibrosarcoma page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myxofibrosarcoma condition card totals 6 registered trials; most-linked intervention CAB-AXL-ADC; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.